<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02259296</url>
  </required_header>
  <id_info>
    <org_study_id>CZHKI-HDVA-001</org_study_id>
    <nct_id>NCT02259296</nct_id>
  </id_info>
  <brief_title>Timing for Arteriovenous Fistula Creation and Its Effect on Target Organs in Patients With Chronic Renal Failure</brief_title>
  <acronym>TACTIC</acronym>
  <official_title>Timing for Arteriovenous Fistula Creation and Its Effect on Target Organs in Patients With Chronic Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Haidian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The timing for arteriovenous fistula (AVF) creation and its effect on target organs in
      patients with chronic renal failure will be investigated by multicenter prospective cohort.
      Lower estimated glomerular filtration rate (eGFR) patients (eGFR&lt;10ml/min 1.73m2 for patients
      without diabetic kidney disease, and eGFR&lt;15ml/min 1.73m2 for diabetic kidney disease) and
      higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease,
      and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) will be proposed to undertake AVF
      creation. Maturation rate and time of AVF will be followed up in 3 months; primary and
      secondary patency rate of AVF, AVF construction on cardiac structure, function,
      encephalopathy, cerebral vascular lesions and cognitive function will be followed up in the
      next 2 years. This multicenter will provide evidence to develop guideline of timing for AVF
      creation
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maturation rate of AVF</measure>
    <time_frame>3 months</time_frame>
    <description>Assessed by duplex ultrasound. A mature fistula has a flow of over 500 mL/min,is less than 0.6 cm below the surface of the skin, and has a minimal diameter of 0.6 cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary and secondary patency rate of AVF</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by duplex ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maturation time of AVF</measure>
    <time_frame>3 months</time_frame>
    <description>Assessed by duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of AVF</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AVF creation on ventricular volumes and left ventricular remodeling</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by doppler echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AVF creation on AVF creation on brain MRI and cognitive functions</measure>
    <time_frame>2 years</time_frame>
    <description>Cognitive functions are assessed by psychic and autonomy scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Renal Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Lower eGFR for AVF creation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher eGFR for AVF creation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lower eGFR for AVF construction</intervention_name>
    <description>Lower eGFR patients (eGFR&lt;10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR&lt;15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction</description>
    <arm_group_label>Lower eGFR for AVF creation</arm_group_label>
    <other_name>late AVF construction</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Higher eGFR for AVF construction</intervention_name>
    <description>Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction</description>
    <arm_group_label>Higher eGFR for AVF creation</arm_group_label>
    <other_name>early AVF construction</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic renal failure, without AVF creation;

          -  Estimated glomerular filtration rate (eGFR) &lt;15ml/min 1.73m2 for patients without
             diabetic kidney disease, and eGFR&lt;20ml/min 1.73m2 for diabetic kidney disease;

          -  All study subjects must agree to participate in the study and provide written informed
             consent.

        Exclusion Criteria:

          -  Patients with the history of arteriovenous graft, or central venous catheter, or
             peritoneal dialysis catheter placement;

          -  Contraindications to AVF construction:

               -  Allen's Test is positive, or arterial diameter＜2 mm; venous diameter＜2.5 mm or
                  venous occlusion/stenosis.

               -  Local infection.

          -  Have any other uncontrolled medical condition (severe heart failure, malignancy,
             severe coagulation disorders ).

          -  Mental illness that makes the patients unable to complete the trial.

          -  Female who is planning to become pregnant, who is pregnant and/or lactating, who is
             unwilling to use effective means of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changlin Mei</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Changzheng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang Gao</last_name>
    <phone>+862181885397</phone>
    <email>gaoxiang43100636@163.com</email>
  </overall_contact>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2014</study_first_posted>
  <last_update_submitted>October 7, 2014</last_update_submitted>
  <last_update_submitted_qc>October 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Changlin Mei</investigator_full_name>
    <investigator_title>Professor, Director, Division of Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

